Kögel Babette, Terlinden Rolf, Schneider Johannes
Grünenthal GmbH, Grünenthal Innovation, Global Preclinical R&D, Aachen, Germany.
Vet Anaesth Analg. 2014 May;41(3):297-304. doi: 10.1111/vaa.12140. Epub 2014 Feb 27.
To evaluate the analgesic potential of the centrally acting analgesics tramadol, morphine and the novel analgesic tapentadol in a pre-clinical research model of acute nociceptive pain, the tail-flick model in dogs.
Prospective part-randomized pre-clinical research trial.
Fifteen male Beagle dogs (HsdCpb:DOBE), aged 12-15 months.
On different occasions separated by at least 1 week, dogs received intravenous (IV) administrations of tramadol (6.81, 10.0 mg kg(-1) ), tapentadol (2.15, 4.64, 6.81 mg kg(-1) ) or morphine (0.464, 0.681, 1.0 mg kg(-1) ) with subsequent measurement of tail withdrawal latencies from a thermal stimulus (for each treatment n = 5). Blood samples were collected immediately after the pharmacodynamic measurements of tramadol to determine pharmacokinetics and the active metabolite O-demethyltramadol (M1).
Tapentadol and morphine induced dose-dependent antinociception with ED50-values of 4.3 mg kg(-1) and 0.71 mg kg(-1) , respectively. In contrast, tramadol did not induce antinociception at any dose tested. Measurements of the serum levels of tramadol and the M1 metabolite revealed only marginal amounts of the M1 metabolite, which explains the absence of the antinociceptive effect of tramadol in this experimental pain model in dogs.
Different breeds of dogs might not or only poorly respond to treatment with tramadol due to low metabolism of the drug. Tapentadol and morphine which act directly on μ-opioid receptors without the need for metabolic activation are demonstrated to induce potent antinociception in the experimental model used and should also provide a reliable pain management in the clinical situation. The non-opioid mechanisms of tramadol do not provide antinociception in this experimental setting. This contrasts to many clinical situations described in the literature, where tramadol appears to provide useful analgesia in dogs for post-operative pain relief and in more chronically pain states.
在犬急性伤害性疼痛的临床前研究模型——甩尾模型中,评估中枢性镇痛药曲马多、吗啡及新型镇痛药氨酚羟考酮的镇痛潜力。
前瞻性部分随机临床前研究试验。
15只12 - 15月龄的雄性比格犬(HsdCpb:DOBE)。
在至少间隔1周的不同时间,犬静脉注射曲马多(6.81、10.0 mg·kg⁻¹)、氨酚羟考酮(2.15、4.64、6.81 mg·kg⁻¹)或吗啡(0.464、0.681、1.0 mg·kg⁻¹),随后测量热刺激引起的甩尾潜伏期(每种治疗n = 5)。在对曲马多进行药效学测量后立即采集血样,以确定药代动力学及活性代谢物O - 去甲基曲马多(M1)。
氨酚羟考酮和吗啡诱导剂量依赖性镇痛作用,ED50值分别为4.3 mg·kg⁻¹和0.71 mg·kg⁻¹。相比之下,曲马多在任何测试剂量下均未诱导镇痛作用。曲马多及其M1代谢物血清水平的测量显示,M1代谢物含量极少,这解释了曲马多在该犬实验性疼痛模型中无镇痛作用的原因。
由于药物代谢率低,不同品种的犬可能对曲马多治疗无反应或反应不佳。在所用实验模型中,直接作用于μ - 阿片受体而无需代谢激活的氨酚羟考酮和吗啡被证明可诱导强效镇痛作用,在临床情况下也应能提供可靠的疼痛管理。在该实验环境中,曲马多的非阿片类机制未产生镇痛作用。这与文献中描述的许多临床情况形成对比,在那些情况中,曲马多似乎能为犬术后疼痛缓解及更慢性疼痛状态提供有效的镇痛作用。